Cardio3 BioSciences , a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company's current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-CureA , and its recently acquired CAR T-cell therapies' portfolio.
http://ift.tt/1LOb7X3
http://ift.tt/1LOb7X3
No comments:
Post a Comment